736
Participants
Start Date
March 31, 2006
Primary Completion Date
October 31, 2007
Study Completion Date
October 31, 2013
Docetaxel
Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
Placebo to bevacizumab
Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
Bevacizumab
Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
Taipei
Taipei
Kaohsiung City
Brussels
Vienna
Camperdown
Westmead
Sandton
Wilrijk
Fitzroy
Box Hill
Ringwood East
Auchenflower
Vöcklabruck
Adelaide
Salzburg
Perth
Chur
Graz
Bangkok
Bangkok
Biella
Caen
Berlin
Hamburg
Dijon
Mexicali
Lund
Jaén
Treviglio
Besançon
Madrid
Málaga
Lemgo
Bordeaux
Udine
Trieste
Montpellier
Khon Kaen
Bologna
Düsseldorf
Modena
Parma
Kaunas
Trier
Linköping
Lille
Frankfurt am Main
Frankfurt
Macerata
Clermont-Ferrand
Monterrey
Heidelberg
Stuttgart
Tübingen
Puebla City
München
Obregón
Ulm
Umeå
Erlangen
Ansbach
Villejuif
Mérida
Taormina
Beijing
Goiânia
Belo Horizonte
Porto Alegre
Florianópolis
Barretos
São Paulo
Calgary
Edmonton
Vancouver
Halifax
Greater Sudbury
Ottawa
Toronto
Montreal
Québec
Halle
Jena
Vilnius
Mexico City
Sittard
Utrecht
Panama City
Krakow
Olsztyn
Poznan
Warsaw
Wroclaw
Coimbra
Lisbon
Bucharest
Pretoria
Seoul
Seoul
Seoul
Barcelona
Barcelona
Barcelona
Barcelona
Bournemouth
Cambridge
Edinburgh
Leeds
Leeds
London
Manchester
Middlesex
Newcastle upon Tyne
Truro
Hoffmann-La Roche
INDUSTRY